6.18
-1.07(-14.76%)
Currency In USD
| Previous Close | 7.25 |
| Open | 7.13 |
| Day High | 7.13 |
| Day Low | 5.9 |
| 52-Week High | 46.68 |
| 52-Week Low | 2.44 |
| Volume | 266,398 |
| Average Volume | 1.45M |
| Market Cap | 17.78M |
| PE | -0.46 |
| EPS | -13.44 |
| Moving Average 50 Days | 5.42 |
| Moving Average 200 Days | 11.1 |
| Change | -1.07 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $63.5 as of August 06, 2025 at a share price of $6.21. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $62.29 as of August 06, 2025 at a share price of $6.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
GlobeNewswire Inc.
Jul 29, 2025 12:00 PM GMT
SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genet
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
GlobeNewswire Inc.
Jul 25, 2025 8:45 PM GMT
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genet
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
GlobeNewswire Inc.
Jul 22, 2025 12:00 PM GMT
SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genet